Anti-Bevacizumab Antibody (AY9) (recommended for ADA assay)
A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) . Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
Product Specifications
Background
Host
Hybridoma
Origin Species
Mouse
Target
Bevacizumab
Conjugation
Unconjugated
Stability
Purity
0.95
Bioactivity
Demonstration of the specificity of Anti-Bevacizumab Antibody (AY9) (Cat. No. BEB-Y9) to the bevacizumab.
Format
Powder
Buffer
Tris with Glycine, Arginine and NaCl, pH7.5
Additives
Trehalose
Additionnal Information
Please see 'Shipping-and-Payments' sheet. Website: https://www.acrobiosystems.com/support/shipping-and-payments
Shipping Conditions
RT
Storage Conditions
-20°C
Package Size
500ug*2
Host or Source
Hybridoma
Species
Mouse
Preservative
Trehalose
Explore Other Products
Browse additional items from our catalog
Complement Factor H-related 2/CFHR2/CFHL2 Recombinant Protein Antigen
FPR2 (N-formyl Peptide Receptor 2, FMLP-related Receptor I, FMLP-R-I, Formyl Peptide Receptor-like 1, HM63, Lipoxin A4 Receptor, LXA4 Receptor, RFP, FPRH1, FPRL1, LXA4R) (MaxLight 750) discontinued
